This study evaluates the efficacy of Thrive, a computerized cognitive behavior therapy program, to reduce depression and anxiety symptoms and to reduce suicidal thinking among adults. The first 450 participants will participate in a randomized waitlist controlled trial. The remaining 550 participants will be provided the program immediately upon enrolling
The efficacy of Thrive has been studied among patient and community populations and has shown to effectively reduce depression and anxiety symptoms among adults with moderate to severe depression symptoms at baseline. This study will examine whether Thrive can also reduce suicidal thinking for persons exhibiting at least moderate depression symptoms. The first phase of the study will implement a randomized waitlist controlled trial. The second phase of the study will examine the effects in a open trial. Outcome assessments will occur at baseline, 4- and 8-weeks (12- and 16-weeks for the waitlist group) with a 6-month follow-up assessment for all participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
725
Computerized Cognitive Behavior Therapy program
Montana State University
Bozeman, Montana, United States
Concise Health Risk Tracking
Suicidal Thinking; Score range 7 (better) - 35(worse)
Time frame: 2 Weeks
Generalized Anxiety Disorder Scale-7
Anxiety symptoms; Score range 0 (better) to 21 (worse)
Time frame: 2 Weeks
Work and Social Adjustment Scale
Functioning; Score range 0(better) - 40(worse)
Time frame: 1 Year
Connor-Davidson Resilience Scale - Abbreviated Version
Resilience; score range 0 (worse) - 40(better)
Time frame: 1 month
Patient Health Questionnaire-9
Depression; Score range 0(better) - 27(worse)
Time frame: 2 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.